Rockefeller Capital Management’s Pacific Biosciences PACB Stock Holding History

Rockefeller Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.98K	Sell	2,368 -2,830	-54%	-$4.12K	﹤0.01%	4298
2026 Q1	$6.86K	Buy	5,198 +3,952	+317%	+$7.07K	﹤0.01%	4141
2025 Q4	$2.33K	Buy	1,246 +989	+385%	+$1.9K	﹤0.01%	4280
2025 Q3	$329	Buy	+257	New	+$348	﹤0.01%	4318
2023 Q1	–	Sell	-1,018	Closed	-$8K	–	3311
2022 Q4	$8K	Buy	1,018 +527	+107%	+$4.54K	﹤0.01%	3188
2022 Q3	$2K	Sell	491 -826	-63%	-$4.74K	﹤0.01%	3614
2022 Q2	$4K	Sell	1,317 -75,579	-98%	-$459K	﹤0.01%	3561
2022 Q1	$699K	Buy	76,896 +76,582	+24,389%	+$882K	﹤0.01%	1191
2021 Q4	$5K	Buy	+314	New	+$7.58K	﹤0.01%	3282
2021 Q3	–	Sell	-4,413	Closed	-$153K	–	3802
2021 Q2	$153K	Sell	4,413 -461	-9%	-$13.4K	﹤0.01%	1625
2021 Q1	$161K	Sell	4,874 -1,456	-23%	-$51K	﹤0.01%	1395
2020 Q4	$164K	Buy	+6,330	New	+$108K	﹤0.01%	1259

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rockefeller Capital Management's PACB Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Pacific Biosciences (PACB) stake by 54% in Q2 2026, selling an estimated $4.12K and leaving 2,368 shares worth $3.98K. The position accounts for ﹤0.01% of the portfolio, ranked #4298.

Rockefeller Capital Management first reported a position in PACB in Q4 2020 and has held it in 12 quarters since. The position peaked at $699K in Q1 2022. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Rockefeller Capital Management held 2,368 shares of Pacific Biosciences worth $3.98K as of Q2 2026.
Rockefeller Capital Management sold 2,830 Pacific Biosciences shares in Q2 2026, an estimated $4.12K.
Pacific Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4298 holding.
Rockefeller Capital Management first reported a position in Pacific Biosciences in Q4 2020 and has held it in 12 quarters since.
Rockefeller Capital Management's Pacific Biosciences position peaked at $699K in Q1 2022.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.